
MindRank’s Dual WEE1/YES1 Kinase Inhibitor, MRANK-106, Receives FDA Green Light for Clinical Trials, Boosting First-in-Class Oncology Pipeline
HANGZHOU, China and LONDON, March 07, 2025 — MindRank, an AI-driven drug discovery firm in the clinical stage, has received […]